44 citations
,
January 2012 in “Food and chemical toxicology” In a testosterone-induced BPH rat model, this study found that ursolic acid treatment significantly reduced prostate weight and hormone levels, suggesting it may inhibit BPH development.
20 citations
,
August 2020 in “Scientific Reports” In this study, low-dose BPA was associated with induced prostatic hyperplasia in rats, potentially mediated by COX-2 and L-PGDS through pathways involving cell proliferation and apoptosis.
5 citations
,
February 2022 in “Supportive Care in Cancer” This study found that age is the most significant risk factor for hemorrhagic cystitis after hematopoietic stem-cell transplantation, with additional risk factors including cyclophosphamide-based prophylaxis and, among male recipients, prostatic hyperplasia.
October 2017 in “Universidad Nacional de Trujillo” This study found that low doses of hydroethanolic extract from Coffea arabica L. seeds reduced prostatic growth in mice with induced prostatic hyperplasia, while both low and high doses lowered uric acid and PSA levels.
January 2007 in “El Servicio de Difusión de la Creación Intelectual (National University of La Plata)” This study found that combining D-004 with finasteride results in more significant prevention of testosterone-induced prostate enlargement in rats compared to using either treatment alone.
January 2002 in “Dialnet (Universidad de la Rioja)” This study found that the epithelial changes in benign prostatic hyperplasia treated with finasteride resembled the pattern of healthy prostates.
12 citations
,
March 2023 in “The FASEB Journal” This study found that platelet-rich plasma treatment significantly improved erectile function and restored neural structures in aged rats with erectile dysfunction, suggesting potential benefits for geriatric patients.
235 citations
,
September 2004 in “The Journal of urology/The journal of urology” This review discusses the role of dihydrotestosterone in benign prostatic hyperplasia and reports no new results; the authors highlight 5alpha-reductase inhibitors as a well-established treatment option.
43 citations
,
August 2016 in “Scientific Reports” This animal study found that Cinnamomi cortex water extract reduced prostate weight and improved histological changes in a benign prostatic hyperplasia model, suggesting potential as a treatment.
35 citations
,
May 2020 in “Frontiers in Pharmacology” This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.
31 citations
,
September 2015 in “BJUI” This study found that men aged 50 and older with clinical benign prostatic hyperplasia have a significantly higher prevalence of metabolic syndrome than those without the condition in the UK primary care population.
30 citations
,
January 2008 in “The Aging Male” This study found no difference in male pattern baldness between patients with benign prostate hyperplasia and prostate cancer, and no correlation with serum androgen levels.
28 citations
,
August 2011 in “Journal of The American Academy of Dermatology” This study found that men with early-onset androgenetic alopecia had significantly larger prostate volumes and lower urinary flow rates compared to healthy controls, suggesting a possible link between AGA and prostate-related urinary symptoms.
26 citations
,
December 2023 in “Prostate International” This review provides an overview of the risks and side effects associated with common medications used to treat benign prostatic hyperplasia, highlighting the importance for clinicians and patients to discuss these aspects for informed decision-making.
24 citations
,
June 2013 in “Expert opinion on pharmacotherapy” This review found dutasteride to be effective, safe, and well-tolerated for treating symptomatic BPH and provides expert commentary on its use, though the relationship with high-grade prostate cancer remains unclear.
24 citations
,
June 2011 in “Andrologia” This study found that Ganoderma lucidum extracts reduced prostate enlargement and improved symptoms in testosterone-treated rats, suggesting potential benefits for managing benign prostatic hyperplasia.
23 citations
,
May 1984 in “Journal of the American Geriatrics Society” Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.
21 citations
,
May 2021 in “Prostate Cancer and Prostatic Diseases” This review analyzes the potential mechanisms by which SARS-CoV-2 may exacerbate symptoms of benign prostatic hyperplasia and suggests a connection via ACE2 and androgen receptor pathways; it reports no new clinical results.
21 citations
,
January 1998 in “Urologia internationalis” This study found that combining dibenyline and finasteride for symptomatic BPH treatment offered modest improvements with fewer additional side effects compared to each drug alone.
20 citations
,
January 2017 in “Nutrition Research and Practice” In this study, corn silk extract treatment improved symptoms of testosterone-induced BPH by reducing specific mRNA expression and decreasing levels of 5α-R2, DHT, and PSA.
20 citations
,
August 2010 in “The Journal of Urology” The study found that ezetimibe effectively reduced prostate enlargement in an animal model of benign prostatic hyperplasia, suggesting it as a potential alternative or complementary treatment.
19 citations
,
October 2018 in “PLOS ONE” This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.
19 citations
,
June 2017 in “Asian journal of urology” This review discusses the stratification and management of male patients with lower urinary tract symptoms and benign prostatic hyperplasia in primary care and reports no new clinical results.
12 citations
,
December 2016 in “Medical Hypotheses” This research suggests that the enzyme Phospholipase D from E. coli is a strong candidate as the underlying cause of benign prostatic hyperplasia, potentially mediated by its conversion to lysophosphatidic acid in the prostate.
11 citations
,
March 2014 in “Journal of The European Academy of Dermatology and Venereology” In this study, researchers found that androgen receptor gene polymorphism is associated with higher androgenetic alopecia grades and PSA levels in men with benign prostatic hyperplasia, but not with prostate cancer.
11 citations
,
April 2013 in “Journal of Agricultural and Food Chemistry” This study found that Monascus cursory extraction reduced baldness, prostate hyperplasia, and tumor incidence in animal models of androgen-related diseases, suggesting it may be a promising new therapeutic candidate.
8 citations
,
August 2021 in “Aging” This animal study found that berberine may alleviate benign prostatic hyperplasia by reducing inflammation and oxidative stress through inhibition of the NF-κB signaling pathway.
6 citations
,
May 2022 in “Research and reports in urology” This study found that Caesalpinia bonduc seed extracts significantly reduced prostate weight and improved prostate tissue morphology in Wistar rats with testosterone-induced benign prostatic hyperplasia.
5 citations
,
June 2015 in “Chinese journal of natural medicines/Zhongguo tianran yaowu/Chinese Journal of Natural Medicines” This study found that Tripterygium wilfordii multiglycoside significantly inhibited testosterone-induced benign prostatic hyperplasia in rats without causing toxicity, suggesting its potential as a therapy for BPH.
5 citations
,
September 2012 in “The Journal of Urology” This article discusses androgenetic alopecia as a potential early marker for benign prostatic hyperplasia but reports no new clinical findings.